{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-339147","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2026-08-07T11:13:34+00:00","discovered_at":"2026-08-07T11:15:04.195530+00:00","generated_at":"2026-08-07T11:15:19.790511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Minerva Q2 GAAP net income $17.5M on $27.6M non-cash warrant gain; adjusted loss $7.8M","bullets":["Q2 2026 GAAP net income of $17.5M ($0.36 basic, $(0.14) diluted) vs net loss of $3.3M year-ago; driven by $27.6M non-cash warrant gain.","Adjusted non-GAAP net loss of $7.8M vs $3.0M year-ago; H1 adjusted loss $15.1M vs $6.4M. Cash $75.4M, down from $82.4M at Dec 31, 2025.","R&D expense $7.2M (Q2) vs $1.3M; G&A $3.5M vs $2.1M, up on C19 trial costs, professional fees and compensation.","Phase 3 C19 roluperidone trial (380 patients, ~40 sites) on track; Phase A topline expected 2H 2027, Phase B 2H 2028.","Scientific Advisory Board expanded to 11 members, adding Correll, Leucht and Sand."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-339147","json":"https://secwatch.observer/filing/0001193125-26-339147.json","markdown":"https://secwatch.observer/filing/0001193125-26-339147.md","text":"https://secwatch.observer/filing/0001193125-26-339147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/0001193125-26-339147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T11:15:19.790511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}